Co-prescription of gastro-protectants in hospitalized patients: an analysis of what we do and what we think we do.
AuthorsDoherty, Glen A
Cannon, Mary D
Lynch, Karen M
Ayoubi, Karim Z
Harewood, Gavin C
Patchett, Stephen E
Murray, Frank E
AffiliationDivision of Gastroenterology and Hepatology, Beaumont Hospital, Royal College of Surgeons, Beaumont, Dublin, Ireland
Aged, 80 and over
Attitude of Health Personnel
Physician's Practice Patterns
Platelet Aggregation Inhibitors
Proton Pump Inhibitors
MetadataShow full item record
CitationCo-prescription of gastro-protectants in hospitalized patients: an analysis of what we do and what we think we do. 2010, 44 (3):e51-6 J. Clin. Gastroenterol.
JournalJournal of clinical gastroenterology
AbstractProton pump inhibitors (PPIs) reduce the risk of upper gastrointestinal hemorrhage (UGIH) associated with the use of many medications.
To examine how clinicians perceive such risk and whether PPI co-prescribing is based on an accurate assessment.
Clinicians in a single teaching hospital were asked to estimate risk of UGIH and comment on PPI co-prescription in hypothetical patients. Records of 160 hospital in-patients (median age; 74 y) were then reviewed to examine PPI prescribing and risk factors for UGIH.
In general, clinicians estimated UGIH risk accurately and reported low thresholds for PPI co-prescription. Prescribing records showed regular PPI use increased between admission and discharge of patients from 61/160 (38%) to 93/160 (58%). Ten percent had a prior history of peptic ulcer disease. Proton pump inhibitor prescription was significantly associated with the use of aspirin and clopidogrel. Half of the patients with multiple risk factors for UGIH on admission and almost a third at discharge were not co-prescribed a PPI.
Clinicians generally estimate correctly the risk of UGIH and report a low threshold for prescribing gastro-protection. Despite this, prescribing practice does not consistently take account of relative risk of UGIH. Targeted PPI co-prescribing on the basis of risk factors would lead to more rational PPI use.
- A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
- Authors: Hsiao FY, Tsai YW, Huang WF, Wen YW, Chen PF, Chang PY, Kuo KN
- Issue date: 2009 Sep
- PPI use in patients commenced on clopidogrel: a retrospective cross-sectional evaluation.
- Authors: Luinstra M, Naunton M, Peterson GM, Bereznicki L
- Issue date: 2010 Apr
- Management of patients with high gastrointestinal risk on antiplatelet therapy.
- Authors: Cryer B
- Issue date: 2009 Jun
- Single antiplatelet therapy for patients with previous gastrointestinal bleeds.
- Authors: Gellatly RM, Ackman ML
- Issue date: 2008 Jun
- Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed.
- Authors: Schreiner GC, Laine L, Murphy SA, Cannon CP
- Issue date: 2007 Dec